Novartis AG ADR (NVS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Novartis AG ADR (NVS) has a cash flow conversion efficiency ratio of 0.140x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($5.89 Billion) by net assets ($41.95 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Novartis AG ADR stock valuation for the company's overall valuation and market capitalisation.
Novartis AG ADR - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Novartis AG ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Novartis AG ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Novartis AG ADR ranked by their cash flow conversion efficiency. Explore earnings quality score of Novartis AG ADR to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AstraZeneca PLC
NASDAQ:AZN
|
0.071x |
|
Royal Bank of Canada
TO:RY
|
0.026x |
|
General Electric Company
SA:GEOO34
|
0.179x |
|
AstraZeneca PLC
MX:AZNN
|
0.048x |
|
China Construction Bank Corporation
F:C6T
|
-0.064x |
|
Novartis AG
MX:NVSN
|
0.094x |
|
RTX Corporation
NYSE:RTX
|
0.061x |
|
Roche Holding AG
SW:ROG
|
0.296x |
Annual Cash Flow Conversion Efficiency for Novartis AG ADR (1998–2025)
The table below shows the annual cash flow conversion efficiency of Novartis AG ADR from 1998 to 2025. View Novartis AG ADR stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $46.55 Billion | $19.24 Billion | 0.413x | +3.53% |
| 2024-12-31 | $44.13 Billion | $17.62 Billion | 0.399x | +29.11% |
| 2023-12-31 | $46.75 Billion | $14.46 Billion | 0.309x | +29.09% |
| 2022-12-31 | $59.42 Billion | $14.24 Billion | 0.240x | +7.81% |
| 2021-12-31 | $67.82 Billion | $15.07 Billion | 0.222x | -7.75% |
| 2020-12-31 | $56.67 Billion | $13.65 Billion | 0.241x | -1.79% |
| 2019-12-31 | $55.55 Billion | $13.62 Billion | 0.245x | +35.24% |
| 2018-12-31 | $78.69 Billion | $14.27 Billion | 0.181x | +6.67% |
| 2017-12-31 | $74.23 Billion | $12.62 Billion | 0.170x | +10.97% |
| 2016-12-31 | $74.89 Billion | $11.47 Billion | 0.153x | -0.67% |
| 2015-12-31 | $77.12 Billion | $11.90 Billion | 0.154x | -21.36% |
| 2014-12-31 | $70.84 Billion | $13.90 Billion | 0.196x | +10.89% |
| 2013-12-31 | $74.47 Billion | $13.17 Billion | 0.177x | -13.73% |
| 2012-12-31 | $69.22 Billion | $14.19 Billion | 0.205x | -5.50% |
| 2011-12-31 | $65.94 Billion | $14.31 Billion | 0.217x | +7.63% |
| 2010-12-31 | $69.77 Billion | $14.07 Billion | 0.202x | -4.97% |
| 2009-12-31 | $57.46 Billion | $12.19 Billion | 0.212x | +9.54% |
| 2008-12-31 | $50.44 Billion | $9.77 Billion | 0.194x | +3.88% |
| 2007-12-31 | $49.40 Billion | $9.21 Billion | 0.186x | -11.60% |
| 2006-12-31 | $41.29 Billion | $8.71 Billion | 0.211x | -13.43% |
| 2005-12-31 | $33.16 Billion | $8.08 Billion | 0.244x | +22.89% |
| 2004-12-31 | $33.92 Billion | $6.72 Billion | 0.198x | -9.04% |
| 2003-12-31 | $30.52 Billion | $6.65 Billion | 0.218x | +6.21% |
| 2002-12-31 | $28.41 Billion | $5.83 Billion | 0.205x | +18.36% |
| 2001-12-31 | $25.56 Billion | $4.43 Billion | 0.173x | -15.86% |
| 2000-12-31 | $22.52 Billion | $4.64 Billion | 0.206x | +11.91% |
| 1999-12-31 | $23.55 Billion | $4.33 Billion | 0.184x | -2.48% |
| 1998-12-31 | $22.66 Billion | $4.28 Billion | 0.189x | -- |
About Novartis AG ADR
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic … Read more